Variation in the use of biologics in the management of rheumatoid arthritis across the UK

References

• Symmons D, Turner G, Webb R, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford) 2002;41:793-800
   PubMed Web of Science ®Google Scholar
• Barrett EM, Scott DG, Wiles NJ, et al. The impact of rheumatoid arthritis on employment status in the early years of disease: a UK community based study. Rheumatology (Oxford) 2000;39:1403-9
   PubMed Web of Science ®Google Scholar
• Young A, Dixey J, Kulinskaya E, et al. Which patients stop working because of rheumatoid arthritis? Results of five years’ follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis 2002;61:335-40
   PubMed Web of Science ®Google Scholar
• Doan QV, Chiou CF, Dubois RW. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J Manag Care Pharm 2006;12:555-69
   PubMed Web of Science ®Google Scholar
• Aletaha D, Smolen JS. The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses. Rheumatology (Oxford) 2002;41:1367-74
   PubMed Web of Science ®Google Scholar
• Kremer JM. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med 2001;134:695-706
   PubMed Web of Science ®Google Scholar
• Moots R, Taggart A, Walker D. Biologic therapy in clinical practice: enthusiasm must be tempered by caution. Rheumatology (Oxford) 2003;42:614-16
   PubMed Web of Science ®Google Scholar
• Yazici Y, Shi N, John A. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. Bull NYU Hosp Jt Dis 2008;66:77-85
   PubMedGoogle Scholar
• Agarwal SK. Biologic agents in rheumatoid arthritis: an update for managed care professionals. J Manag Care Pharm 2011;17(9 Suppl B):S14-18
   PubMed Web of Science ®Google Scholar
• Kay LJ, Griffiths ID; BSR Biologics Register Management committee. UK consultant rheumatologists’ access to biological agents and views on the BSR Biologics Register. Rheumatology (Oxford) 2006;45:1376-9
   PubMed Web of Science ®Google Scholar
• TA130. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis – TA130. Available at: http://guidance.nice.org.uk/TA130 [Last accessed 2 July 2012]
   Google Scholar
• Hyrich KL, Symmons DP, Watson KD, et al. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:1786-94
   PubMed Web of Science ®Google Scholar
• TA186. Certolizumab pegol for the treatment of rheumatoid arthritis – TA186. Available at: http://guidance.nice.org.uk/TA186 [Last accessed 2 July 2012]
   Google Scholar
• TA195. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor - TA195. Available at: http://guidance.nice.org.uk/TA195 [Last accessed 2 July 2012]
   Google Scholar
• TA198. Tocilizumab for rheumatoid arthritis – TA198. Available at: http://guidance.nice.org.uk/TA198 [Last accessed 2 July 2012]
   Google Scholar
• EFPIA: Access to Innovative Treatments in Rheumatoid Arthritis in Europe, October 2009. A Report Prepared for the European Federation of Pharmaceutical Industry Associations (EFPIA). Available at: http://www.lif.se/default.aspx?id=44400 [Last accessed 2 July 2012]
   Google Scholar
• Miltenburger C, Günther OH, Justo N, et al. A Survey of Barriers to Treatment Access in Rheumatoid Arthritis in France, Germany, Italy, Spain and the UK, October 2009. Available at: http://www.comparatorreports.se/cr02a_products.htm [Last accessed 2 July 2012]
   Google Scholar
• Arthritis Research Campaign (2002) Arthritis: The Big Picture. Chesterfield: Arthritis Research Campaign. Available at: http://www.ipsos-mori.com/Assets/Docs/Archive/Polls/arthritis.pdf [Last accessed 2 July 2012]
   Google Scholar
• Kiely P, Walsh D, Williams R, Young A; Early Rheumatoid Arthritis Network. Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity – the early RA network (ERAN). Rheumatology (Oxford) 2011;50:926-31
   PubMed Web of Science ®Google Scholar
• Soubrier M, Lukas C, Sibilia J, et al. Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort. Ann Rheum Dis 2011;70:611-15
   PubMed Web of Science ®Google Scholar
• Soliman MM, Ashcroft DM, Watson KD, et al. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011;70:583-9
   PubMed Web of Science ®Google Scholar
• Askling J, Fored CM, Brandt L, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007;66:1339-44
   PubMed Web of Science ®Google Scholar
• Listing J, Strangfeld A, Rau R, et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low – results from RABBIT, the German biologics register. Arthritis Res Ther 2006;8:R66
   PubMed Web of Science ®Google Scholar
• Penn H. Biologic therapies in autoimmune diseases. Clin Med 2006;6:105-8
   PubMed Web of Science ®Google Scholar
• Strand V, Sokolove J. Randomized controlled trial design in rheumatoid arthritis: the past decade. Arthritis Res Ther 2009;11:205
   PubMedGoogle Scholar
• Breedveld FC, Combe B. Understanding emerging treatment paradigms in rheumatoid arthritis. Arthritis Res Ther 2011;13(Suppl 1):S3
   PubMedGoogle Scholar
• Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 2009;68:1094-9
   PubMed Web of Science ®Google Scholar
• Contreras-Yáñez I, Ponce De León S, Cabiedes J, et al. Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease-modifying antirheumatic drugs. Am J Med Sci 2010;340:282-90
   PubMed Web of Science ®Google Scholar
• de Klerk E, van der Heijde D, Landewé R, et al. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol 2003;30:44-54
   PubMed Web of Science ®Google Scholar
• Singh JA, Christensen R, Wells GA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009;4:CD007848
   PubMed Web of Science ®Google Scholar
• Devine EB, Alfonso-Cristancho R, Sullivan SD. Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach. Pharmacotherapy 2011;31:39-51
   PubMed Web of Science ®Google Scholar
• Deighton C. If it works why can’t we have it? Sequential anti-TNF therapy in the UK. Why sequential anti-TNF use remains restricted in the UK. Rheumatology 2010;49:2235-6
   PubMedGoogle Scholar